671 related articles for article (PubMed ID: 9650561)
1. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
[TBL] [Abstract][Full Text] [Related]
2. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
Weiner GJ; Kostelny SA; Hillstrom JR; Cole MS; Link BK; Wang SL; Tso JY
J Immunol; 1994 Mar; 152(5):2385-92. PubMed ID: 8133049
[TBL] [Abstract][Full Text] [Related]
3. T cell activation and cytokine production in anti-CD3 bispecific antibody therapy.
Belani R; Weiner GJ
J Hematother; 1995 Oct; 4(5):395-402. PubMed ID: 8581375
[TBL] [Abstract][Full Text] [Related]
4. Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab')2 for efficient lysis of p185HER2 overexpressing tumor cells.
Zhu Z; Lewis GD; Carter P
Int J Cancer; 1995 Jul; 62(3):319-24. PubMed ID: 7628874
[TBL] [Abstract][Full Text] [Related]
5. Production and characterization of a bispecific IgG capable of inducing T-cell-mediated lysis of malignant B cells.
Link BK; Weiner GJ
Blood; 1993 Jun; 81(12):3343-9. PubMed ID: 8507872
[TBL] [Abstract][Full Text] [Related]
6. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
Tutt A; Stevenson GT; Glennie MJ
J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
[TBL] [Abstract][Full Text] [Related]
7. Influence of the bispecific antibody IgG subclass on T cell redirection.
Kapelski S; Cleiren E; Attar RM; Philippar U; Häsler J; Chiu ML
MAbs; 2019; 11(6):1012-1024. PubMed ID: 31242061
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
Chapoval AI; Nelson H; Thibault C
J Immunol; 1995 Aug; 155(3):1296-303. PubMed ID: 7636196
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.
Negri DR; Tosi E; Valota O; Ferrini S; Cambiaggi A; Sforzini S; Silvani A; Ruffini PA; Colnaghi MI; Canevari S
Br J Cancer; 1995 Oct; 72(4):928-33. PubMed ID: 7547242
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
[TBL] [Abstract][Full Text] [Related]
11. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
Rodrigues ML; Shalaby MR; Werther W; Presta L; Carter P
Int J Cancer Suppl; 1992; 7():45-50. PubMed ID: 1428403
[TBL] [Abstract][Full Text] [Related]
12. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.
Luiten RM; Warnaar SO; Sanborn D; Lamers CH; Bolhuis RL; Litvinov SV; Zurawski VR; Coney LR
J Immunother; 1997 Nov; 20(6):496-504. PubMed ID: 9409456
[TBL] [Abstract][Full Text] [Related]
13. Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation.
Ledbetter JA; June CH; Martin PJ; Spooner CE; Hansen JA; Meier KE
J Immunol; 1986 Jun; 136(11):3945-52. PubMed ID: 3084650
[TBL] [Abstract][Full Text] [Related]
14. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity.
van Dijk J; Zegveld ST; Fleuren GJ; Warnaar SO
Int J Cancer; 1991 Jul; 48(5):738-43. PubMed ID: 1830033
[TBL] [Abstract][Full Text] [Related]
15. Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 x CD19.
Klein SC; Boer LH; de Weger RA; de Gast GC; Bast EJ
Scand J Immunol; 1997 Nov; 46(5):452-8. PubMed ID: 9393627
[TBL] [Abstract][Full Text] [Related]
16. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
Trinklein ND; Pham D; Schellenberger U; Buelow B; Boudreau A; Choudhry P; Clarke SC; Dang K; Harris KE; Iyer S; Jorgensen B; Pratap PP; Rangaswamy US; Ugamraj HS; Vafa O; Wiita AP; van Schooten W; Buelow R; Force Aldred S
MAbs; 2019; 11(4):639-652. PubMed ID: 30698484
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2.
Haagen IA; Geerars AJ; de Lau WB; Bast BJ; de Gast BC
Blood; 1995 Jun; 85(11):3208-12. PubMed ID: 7538821
[TBL] [Abstract][Full Text] [Related]
18. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect.
Eissler N; Ruf P; Mysliwietz J; Lindhofer H; Mocikat R
Cancer Res; 2012 Aug; 72(16):3958-66. PubMed ID: 22745368
[TBL] [Abstract][Full Text] [Related]
19. Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1.
Kroesen BJ; Nieken J; Sleijfer DT; Molema G; de Vries EG; Groen HJ; Helfrich W; The TH; Mulder NH; de Leij L
Cancer Immunol Immunother; 1997; 45(3-4):203-6. PubMed ID: 9435874
[TBL] [Abstract][Full Text] [Related]
20. Targeting of T lymphocytes against EGF-receptor+ tumor cells by bispecific monoclonal antibodies: requirement of CD3 molecule cross-linking for T-cell activation.
Ferrini S; Cambiaggi A; Sforzini S; Marciano S; Canevari S; Mezzanzanica D; Colnaghi MI; Grossi CE; Moretta L
Int J Cancer; 1993 Dec; 55(6):931-7. PubMed ID: 8253530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
